Valion Bio, Inc.

For the period ended Dec 31, 2024. Filed Mar 21, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 21, 2025

VBIO$0.54+6.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

December 31, 2024 and 2023

(in thousands, except share and per share data)

	December 31,2024	December 31,2023
ASSETS
Current assets
Cash and cash equivalents	$2,002	$3,395
Accounts receivable, net	69	174
Inventory, net	319	756
Prepaid expenses and other current assets	249	327
Total current assets	2,639	4,652
Property and equipment, net	119	122
Right-of-use assets, operating lease	—	349
Deferred offering costs	49	—
Other assets	—	34
Total assets	$2,807	$5,157
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$125	$713
Other accrued expenses	147	495
Operating lease liability, current	—	193
Total current liabilities	272	1,401
Operating lease liability	—	176
Total liabilities	272	1,577
Commitments and contingencies (Note 6)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at December 31, 2024 and 2023, respectively	—	—
Common stock, $0.0001 par value, 200,000,000 shares authorized; 556,978 and 86,241 shares issued and outstanding at December 31, 2024 and 2023, respectively	1	—
Additional paid in capital	46,075	41,466
Accumulated deficit	(43,541)	(37,886)
Total stockholders’ equity	2,535	3,580
Total liabilities and stockholders’ equity	$2,807	$5,157

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.